Recent work demonstrated the ability to accurately predict SCLC transformation in EGFR-mutant LUAD patients from cell-free DNA using a specific epigenetic signature [98], highlighting the exciting potential for this approach, although significant validation on diverse cohorts will be required to deploy this for clinical use. This evidence concerns the gene EGFR and small cell lung carcinoma.